Bausch + Lomb Will Acquire XIIDRA®
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- S&P 500, Nasdaq fall as investors juggle earnings, Mideast risks and tariffs
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil retreats from above $100, still set for weekly rise on Middle East escalation
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- Americold to wind down Ahold Delhaize facilities, take $305M charge
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Did Google and Tesla just break AI trade’s bull case?
Bausch & Lomb Corp. (BLCO) PT Raised to $23 at BofA Securities on new acquisition
July 3, 2023 6:53 AM EDTBofA Securities analyst Craig Bijou raised the price target on Bausch & Lomb Corp. (NYSE: BLCO) to $23.00 (from $19.00) while maintaining a Buy rating.
The analyst is positive on the acquisition of Novartis dry eye disease (DED) drug.
"We see the deal as a meaningful... More
Bausch + Lomb Corporation (BLCO) shares surge on $2.5bn deal to acquire XIIDRA
June 30, 2023 11:19 AM EDTBausch + Lomb Corporation (NYSE: BLCO) shares surged Friday after the company announced a deal to acquire XIIDRA from Novartis for up to $2.5 billion.
BLCO shares are currently up more than 5% at $20.20 after initially hitting a high of $21.95 per share.
The company, through an affiliate, will acquire XIIDRA, libvatrep, and AcuStream in a deal worth up to $2.5 billion, including an upfront payment of $1.75 billion in cash with potential milestone obligations up... More
